▲ +87.59% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Surgalign in the last 3 months. The average price target is $4.33, with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 87.59% upside from the last price of $2.31.
The current consensus among 4 investment analysts is to buy stock in Surgalign.
Surgalign Holdings, Inc., a medical technology company, designs, develops, manufactures, and distributes biologic, metal, and synthetic implants worldwide. It offers coflex interlaminar stabilization device, an implant for the treatment of moderate to severe lumbar spinal stenosis in conjunction with decompression; SImmetry sacroiliac joint fusion system, which decreases in opioid use, pain, and disability; and Fortilink IBF system with TETRAfuse ?3D technology. The company's implants are used in the fields of orthopedic, spine, sports medicine, plastic surgery, trauma, and other surgical procedures to repair and promote the natural healing of human bone and other human tissues; and to enhance surgical outcomes. It markets its products through its direct distribution force and various OEM relationships to healthcare providers, hospitals, and other healthcare facilities, as well as through a network of independent distributors. The company was founded in 1997 and is headquartered in Deerfield, Illinois.